What a difference one year can make. In 2011, Astex Pharmaceuticals shareholders saw the stock plummet by 30%. The next year, though, shares rebounded by nearly 50%. What kind of year will 2013 be for ...

When considering any stock for your portfolio, don't be swayed by just the positives. Examine its pros and cons and decide whether its possible upside outweighs its risks. Let's take a look at Astex ...

Kenilworth-based Merck announced on Monday an exclusive worldwide research collaboration and license agreement. “At Merck we continue to pursue new regimens designed to extend the benefits of highly ...

Another domino has fallen in the world of biotech. Astex Pharmaceuticals (NASDAQ: ASTX) is being scooped up by Tokyo-based Otsuka Pharmaceuticals. Otsuka announced on Thursday that it plans to buy ...

ASTX528 is a novel small molecule CBP/p300 HAT domain inhibitor with potent in vivo activity and a favourable safety profile in preclinical species that was discovered by Astex using its proprietary ...

Astex grants worldwide license to Janssen Pharmaceutica to develop and commercialise compounds arising from Astex's novel FGFR inhibitor programme and establishes a novel drug discovery programme ...

DUBLIN, Calif. & CAMBRIDGE, United Kingdom--(BUSINESS WIRE)--SuperGen, Inc. (NASDAQ:SUPG), a U.S.-based pharmaceutical company dedicated to the discovery and development of novel cancer therapies, and ...

CAMBRIDGE, England, April 24, 2025--(BUSINESS WIRE)--Mosaic Therapeutics, Ltd (‘Mosaic’, or ‘the Company’) a targeted oncology therapeutics company dedicated to resolving cancer’s complexity with new ...

In the latest buyout of what’s been a busy M&A week, Japanese drug maker Otsuka inked an $886 million pact on Thursday to snag U.S. cancer treatment maker Astex (NASDAQ:ASTX). The deal will allow ...

NEW YORK (AP) -- Shares of Astex Pharmaceuticals Inc. rose Wednesday after the company said it received a $5.4 million payment from its partner Johnson & Johnson. THE SPARK: Astex said J&J's Janssen ...

What to watch this year with Astex Pharmaceuticals. What a difference one year can make. In 2011, Astex Pharmaceuticals (NASDAQ: ASTX) shareholders saw the stock plummet by 30%. The next year, though, ...